Equaly

Executive Summary

Equaly is a Belgian biotech startup developing a novel immunotherapy platform that modulates immune responses through antigen-specific cells of the innate immune system. Unlike conventional approaches that broadly activate or suppress immunity, Equaly's technology enables precise targeting of specific antigens, potentially offering safer and more effective treatments for cancer, infectious diseases, and autoimmune disorders. The platform is designed to produce next-generation biologics by harnessing the innate immune system's natural ability to recognize and respond to pathogens and abnormal cells, opening new avenues for therapies that are currently limited by off-target effects or insufficient efficacy. Founded in 2019 and based in Leuven, Belgium, Equaly is still in its early stages, with no disclosed funding or clinical-stage programs, but its unique antigen-specific tuning mechanism positions it as a promising player in the immuno-oncology and immunotherapy landscape.

Upcoming Catalysts (preview)

• Q3 2026Publication of preclinical proof-of-concept data in a peer-reviewed journal70% success
• Q4 2026Completion of Series A financing round to advance lead candidate into IND-enabling studies60% success
• TBDAnnouncement of a strategic research collaboration with a pharmaceutical or academic partner50% success